[go: up one dir, main page]

MX2014011116A - Tratamiento de cancer con inhibidores de tor cinasa. - Google Patents

Tratamiento de cancer con inhibidores de tor cinasa.

Info

Publication number
MX2014011116A
MX2014011116A MX2014011116A MX2014011116A MX2014011116A MX 2014011116 A MX2014011116 A MX 2014011116A MX 2014011116 A MX2014011116 A MX 2014011116A MX 2014011116 A MX2014011116 A MX 2014011116A MX 2014011116 A MX2014011116 A MX 2014011116A
Authority
MX
Mexico
Prior art keywords
tor
cancer treatment
cinasa
inhibitors
castration
Prior art date
Application number
MX2014011116A
Other languages
English (en)
Other versions
MX359227B (es
Inventor
Shuichan Xu
Kristen Mae Hege
Heather Raymon
Toshiya Tsuji
Lisa Sapinoso
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of MX2014011116A publication Critical patent/MX2014011116A/es
Publication of MX359227B publication Critical patent/MX359227B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G01N33/57555—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se proporcionan en la presente métodos para tratar o prevenir el cáncer de próstata resistente a la castración que sobreexpresa ETS, que comprende administrar una cantidad efectiva de un inhibidor de TOR cinasa a un paciente que tiene cáncer de próstata resistente a la castración que sobreexpresa (ETS).
MX2014011116A 2012-03-15 2013-03-14 Tratamiento de cáncer con inhibidores de tor cinasa. MX359227B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261611428P 2012-03-15 2012-03-15
US201261715327P 2012-10-18 2012-10-18
PCT/US2013/031217 WO2013138560A1 (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2014011116A true MX2014011116A (es) 2015-04-08
MX359227B MX359227B (es) 2018-09-20

Family

ID=48045717

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011116A MX359227B (es) 2012-03-15 2013-03-14 Tratamiento de cáncer con inhibidores de tor cinasa.

Country Status (21)

Country Link
US (1) US20130245028A1 (es)
EP (1) EP2825171B1 (es)
JP (2) JP2015511964A (es)
KR (1) KR102057357B1 (es)
CN (2) CN104271138A (es)
AU (2) AU2013202992B2 (es)
BR (1) BR112014022700A2 (es)
CA (1) CA2867174C (es)
EA (1) EA028062B1 (es)
ES (1) ES2668279T3 (es)
IL (1) IL234639B (es)
MX (1) MX359227B (es)
MY (1) MY198666A (es)
NI (1) NI201400110A (es)
NZ (1) NZ628420A (es)
PH (1) PH12014502047B1 (es)
SG (1) SG11201405686PA (es)
TW (1) TWI622395B (es)
UA (1) UA114194C2 (es)
WO (1) WO2013138560A1 (es)
ZA (1) ZA201406708B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EA201591327A1 (ru) 2013-01-16 2015-12-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Замещенные пирролопиримидиновые соединения, их композиции и способы лечения с использованием таких соединений
JP6382946B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
MX377267B (es) 2013-04-17 2025-03-07 Signal Pharm Llc Tratamiento de cáncer con dihidropirazino-pirazinas.
TWI631949B (zh) 2013-04-17 2018-08-11 標誌製藥公司 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
SG10201708111YA (en) 2013-04-17 2017-11-29 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
CA2909629C (en) 2013-04-17 2022-12-13 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
TW201521725A (zh) 2013-04-17 2015-06-16 Signal Pharm Llc 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
CA3143529A1 (en) 2013-05-29 2014-12-04 Signal Pharmaceuticals, Llc Pharmaceutical compositions 0f 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
EP3131551A4 (en) 2014-04-16 2017-09-20 Signal Pharmaceuticals, LLC SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
AU2015289929A1 (en) 2014-07-14 2017-03-02 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
WO2016210046A1 (en) * 2015-06-24 2016-12-29 Celgene Corporation Treatment of cancer with dnapk inhibitors
US11318139B2 (en) 2016-01-26 2022-05-03 Dana-Farber Cancer Institute, Inc. Methods for treating brain metastases using combinations of anti-P13K and anti-mTOR agents
BR112019027402A2 (pt) 2017-06-22 2020-07-07 Celgene Corporation tratamento de carcinoma hepatocelular caracterizado por infecção pelo vírus da hepatite b

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2631003T3 (es) * 2006-10-19 2017-08-25 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y métodos de tratamiento con ellos
US7968556B2 (en) * 2006-10-19 2011-06-28 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and methods of treatment therewith
JP5279828B2 (ja) * 2008-07-10 2013-09-04 Ｊｘ日鉱日石金属株式会社 ハイブリッドシリコンウエハ及びその製造方法
CA2734828C (en) * 2008-08-20 2018-07-24 J. Silvio Gutkind Chemoprevention of head and neck squamous cell carcinomas
WO2010044893A1 (en) * 2008-10-17 2010-04-22 Merck & Co. Combination therapy
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
WO2010058572A1 (en) * 2008-11-20 2010-05-27 Oncotherapy Science, Inc. Methods for diagnosing or treating prostate cancer
US20120190666A1 (en) * 2009-05-13 2012-07-26 Amgen Inc. Heteroaryl Compounds as PIKK Inhibitors
KR20120091240A (ko) 2009-10-26 2012-08-17 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물의 합성 및 정제 방법
AR078793A1 (es) * 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros

Also Published As

Publication number Publication date
CA2867174A1 (en) 2013-09-19
NI201400110A (es) 2015-01-12
IL234639B (en) 2020-05-31
AU2013202992B2 (en) 2015-09-03
SG11201405686PA (en) 2014-10-30
KR20140138928A (ko) 2014-12-04
ZA201406708B (en) 2016-05-25
PH12014502047A1 (en) 2014-12-10
EP2825171A1 (en) 2015-01-21
WO2013138560A1 (en) 2013-09-19
JP2018058861A (ja) 2018-04-12
ES2668279T3 (es) 2018-05-17
TWI622395B (zh) 2018-05-01
EP2825171B1 (en) 2018-03-14
CA2867174C (en) 2020-06-23
EA201491701A1 (ru) 2015-01-30
HK1202247A1 (en) 2015-09-25
JP2015511964A (ja) 2015-04-23
MY198666A (en) 2023-09-14
BR112014022700A2 (pt) 2020-06-30
MX359227B (es) 2018-09-20
AU2015213353A1 (en) 2015-09-03
KR102057357B1 (ko) 2019-12-18
IL234639A0 (en) 2014-11-30
EA028062B1 (ru) 2017-10-31
AU2013202992A1 (en) 2013-10-03
PH12014502047B1 (en) 2014-12-10
CN104271138A (zh) 2015-01-07
UA114194C2 (uk) 2017-05-10
NZ628420A (en) 2016-04-29
TW201343166A (zh) 2013-11-01
CN109846884A (zh) 2019-06-07
JP6470822B2 (ja) 2019-02-13
AU2015213353B2 (en) 2017-07-27
US20130245028A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
MX2014011116A (es) Tratamiento de cancer con inhibidores de tor cinasa.
PH12018502234B1 (en) Treatment of cancer with tor kinase inhibitors
MX373925B (es) Tratamiento del cancer con inhibidores de tor cinasa.
MX2015014596A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer.
MX2015014591A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
MX2017010773A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte progamada 1 (pd-l1) para el tratamiento de cancer.
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
NI201400095A (es) Metodos para el tratamiento del cáncer de pulmon de celulas no pequeñas utilizando terapia combinada de inhibidor tor cinasa.
NI201400112A (es) Tratamiento del cáncer con inhibidores tor cinasa
NI201500055A (es) Tratamiento de cáncer de próstata con inhibidores de quinasa tor
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
NI201500151A (es) Terapia de combinación que comprende un compuesto de dihidropirazino-pirazina y un antagonista de receptor de andrógenos para tratar cáncer de próstata.
MX2017009246A (es) Farmaco de combinacion.
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.
UY35033A (es) Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa
CR20140480A (es) Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek
GT201300148A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de p13k y un inhibidor de mek

Legal Events

Date Code Title Description
FG Grant or registration